New drug development campus plans unveiled
13 October 2009
The project aims to create a world-leading hub for early-stage biotech companies, operating under a model of open-innovation and collaboration.
The Campus will offer each company access to specialist skills, equipment and expertise, to help stimulate innovation in drug development. By sharing knowledge, each company will also increase its chance of success while retaining its independence so entrepreneurship can flourish.
Speaking ahead of the announcement at the Technology Strategy Board's Innovate 09 Conference, Lord Mandelson said: "Innovation drives commercial invention; it pushes up productivity; it is at the heart of growth. And this joint investment by the public, private and charitable sectors recognises that innovation will be decisive in Britain's recovery.
"The Stevenage Campus represents a huge investment in the future of Britain's bioscience industry and is a strong new platform for the work of our Office for Life Sciences. It will leverage our existing strengths as a world leader in the sector, helping it to grow and reinforcing our international competitiveness. And ultimately it will help us build towards a stronger UK economy coming out of the global downturn."
Sir Mark Walport, Director of the Wellcome Trust, said: "We welcome this new public-private partnership, which will catalyse the development of new healthcare products. This initiative will help us achieve an important part of our charitable mission, which is to translate research into health benefit.
"The new Campus will provide state-of-the-art facilities and mentorship for research teams and start-up companies embedded at the heart of GSK's R&D facilities in Stevenage and near to academic centres of excellence in the South East, including the developing UK Centre for Medical Research and Innovation at St Pancras."
It is estimated that development of the campus could create up to 1500 new jobs, most of which will be high-skilled. It will initially be home to around 25 companies, co-located with GlaxoSmithKline on its existing research site, with plans to increase capacity at the park fivefold over the next ten years.
Andrew Witty, CEO of GlaxoSmithKline said: "GSK is delighted to play a leading role in the creation of this science park on our Stevenage site. Innovation is at the heart of the life-sciences industry and this park will provide a supportive environment where scientists in small biotech companies can tap into GSK's management and expertise in drug discovery while remaining independent.
"This collaboration in turn will stimulate innovation that will help ensure the UK remains a world-leader in the research and development of important medicines."
Total investment in the Campus stands at around £37.6 million. On top of £11.7 million from the Government's UK Strategic Investment Fund, GlaxoSmithKline has granted £10.9 million, the Wellcome Trust has committed £6 million, the Technology Strategy Board is providing £5 million and EEDA will look to contribute £4 million.
Image: Artist's impression of the Campus, courtesy of the Department for Business, Innovation and Skills